
    
      This study consists of two cohorts (Cohort 1 [Single-dose Cohort], and Cohort 2 [Repeat-dose
      Cohort]). Up to approximately 24 participants will be enrolled in this study, in which up to
      12 participants may be enrolled into Cohort 1. However, Cohort 1 will be closed upon
      implementation of Amendment 2. Approximately 12 participants will be enrolled in Cohort 2.
      Participants will be randomized in 3:1 ratio (9 lanadelumab: 3 placebo) in each Cohort.
    
  